High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013 LEARN MORE>
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013
>Go!

Research and Development

Actavis has 17 principal global R&D facilities focused on identifying and pursuing global product development opportunities across all three of its core product businesses.

Research and development activities capitalize on the Company’s expertise in numerous drug delivery technologies, including solid dosage from, oral-controlled and sustained release, semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, respiratory and other drug delivery technologies and the application of these technologies to proprietary drug forms.